Tag - IGC

Developments

IGC announces pre-clinical data for TGR-63 in AD

IGC Pharma (NYSE: IGC) has announced preclinical findings on its investigational small molecule candidate for Alzheimer’s disease (AD) demonstrating that TGR-63 extends its therapeutic potential beyond previously...

September 24, 2025

Developments

IGC reports positive preclinical data on IGC-M3 in Alzheimer’s

IGC Pharma (NYSE: IGC) has announced promising preclinical results of its novel small molecule, IGC-M3, designed to address multiple biological drivers of Alzheimer’s disease. According to IGC, IGC-M3 demonstrated...

August 12, 2025

Tag - IGC

IGC announces pre-clinical data for TGR-63 in AD

IGC reports positive preclinical data on IGC-M3 in Alzheimer’s

Subscribe